

New governance for BetaGlue Technologies

The Shareholders' Meeting renews the BoD: Dr Colin Story appointed CEO

The Board of Directors welcomes new Board Members Giovanni Cerutti and Luca Melindo.

The Directors, with their strong experience and comprehensive knowledge of the Life Sciences and Biotech industries, will support the company's future growth.

Milan, February 27, 2023 – The Ordinary Shareholder's Meeting of **BetaGlue Technologies SpA**, a clinical stage company developing novel medical device products with a primary focus in the field of loco-regional radiotherapy to treat solid tumour cancer patients, today announced the appointment of the new Board of Directors.

Colin Story, Giovanni Cerutti and Luca Melindo have been appointed Directors of the Company, while **Diana Saraceni, Claudio Giuliano, Michel Therin** are re-elected, as well as **Riccardo Palmisano**, who remains in office as Chairman. The new Members of the Board **appointed Colin Story as CEO of BetaGlue Technologies**.

BetaGlue Technologies' CEO, Colin Story, said: «*BetaGlue's clinical development programmes hold great promise to significantly benefit patients and healthcare providers and I'm delighted to be appointed CEO at this very exciting stage in the company's evolution. The talented team at BetaGlue, both past and present, have made tremendous progress and as a team we'll be working hard to build on this foundation with a primary focus of bringing new and innovative targeted radiotherapy treatment options to cancer patients*».

Thanks to their strong experience and comprehensive knowledge of the industry, the newly appointed Board Members are yet another valuable addition that can strengthen BetaGlue's Governing Body and will provide additional support to the Company's future growth.

Chairman, Riccardo Palmisano, commented: «*We welcome Colin Story at the helm of the Company. I am confident that he will be able to lead BetaGlue towards ambitious development goals, which will create value for patients, clinicians and Shareholders. We would like to express our heartfelt thanks to Tony Amato, which is leaving his roles as CEO and CMO, for the passion and determination he has poured into his outstanding work and strong commitment during the years. His work was key in building the strong foundations that will allow the company to navigate future challenges with confidence*».

Profiles of the new Directors

Colin Story brings over 25 years of medical technology and Life Sciences industry experience. After graduating with a PhD in Molecular Biology, he started his career at Amersham plc (now GE Healthcare) where he headed a global commercial role with full P&L accountability. In 2005, he joined Isis Innovation, while in 2011, he was invited to join OrganOx as Operations Director, leading the business in the translation of its class III medical device from prototype through to successful completion of first in-human clinical trials. Dr Story co-founded OxSonics in 2013 and served as CEO from January 2014 through to January 2022. Under his leadership, a total of £25m was raised and OxSonics' proprietary 'SonoTran' platform technology transitioned into clinical use. He built out the executive team of 30 and the Board. He also led OxSonics through a corporate restructuring in

2016 to create sister company OrthoSon, raising £1m seed capital. Dr Story also currently holds the position of Non-Executive Director of Hox Therapeutics, a biotechnology company focussed on the treatment of Prostate Cancer.

Giovanni Cerutti is Business Unit Head in Advanced Accelerator Applications (AAA), a Novartis Company. He has a wealth of experience as a seasoned Commercial Director in AAA Italy and former Country Business Manager Italy in GE HealthCare/Amersham, launching a loco-regional oncologic radiotherapy platform, and over 30 years of working experience in the pharmaceutical (Rx, medical diagnostics) and healthcare (surgical active implantable medical devices – AIMD - and medical equipment) industry. He boasts a proven track record in managing start-up branches, growing market share and profitability, with extensive experience in the investment world (financial evaluation of product acquisitions, M&A). At the companies where he has served, he has held roles in both the head offices and subsidiaries, and in different departments (Injectable Drugs Manufacturing, Quality Assurance, Technical Direction).

Luca Melindo has twenty years of experience in Private Equity and Venture Capital. He managed investment and divestment deals with significant returns on invested capital. He boasts a sound expertise in management control, corporate finance, M&A and management of corporate activities. He currently holds several corporate offices, also with operational powers, and works, as a consultant, with an investment fund operating in the biotech sector.

BetaGlue Technologies SpA

BetaGlue Technologies is a highly innovative company working in the Life Sciences sector. The Company has developed BAT-90, an advanced radiotherapy platform targeting inoperable solid tumours and/or surgical resection margins. BetaGlue enjoys the support of a highly qualified Scientific Advisory Board, as well as of leading national and international advisers, in the development of its products.

Web site: www.betaglue.com

LinkedIn: www.linkedin.com/company/betaglue-technologies

Mail: info@betaglue.com

Media contacts

Francesca Pedrali

Comunicazione BetaGlue

f.pedrali@betaglue.it

+39 339 7675434

Community - Reputation Advisers

betaglue@community.it

Giuliano Pasini

Giulia Vaccaro | +39 342 0865017

Federico Nascimben | +39 351 1059957